Emerging Role of Probiotics in the Management of Helicobacter Pylori Infection: Histopathologic Perspectives

Helicobacter

Volumn 21, Issue 1, 2016, Pages 3-10

  Emara, Mohamed H ^a   Elhawari, Soha A ^a   Yousef, Salem ^a   Radwan, Mohamed I ^a   Abdel Aziz, Hesham R ^a  

^a ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

Helicobacter pylori; Gastric activity score; Gastric inflammatory cell score; Gastritis; Probiotics; Sydney classification system

Indexed keywords

CLARITHROMYCIN; PROBIOTIC AGENT;

BIFIDOBACTERIUM ANIMALIS; CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS JOHNSONII; LACTOBACILLUS REUTERI; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH ANTRUM; STOMACH DISTENSION; STOMACH EPITHELIUM; SUPPLEMENTATION; TASTE DISORDER; VOMITING; ANIMAL; DRUG EFFECTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY;

ANIMALS; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROBIOTICS;

EID: 84958851143     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12237     Document Type: Review

References (42)

1. Franceschi F, Zuccalà G, Roccarina D, Gasbarrini A. Clinical effects of Helicobacter pylori outside the stomach. Nat Rev Gastroenterol Hepatol 2014;11:234-42.
2. Blaser MJ. Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. J Infect Dis 1999;179:1523-30.
3. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infectionthe Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64.
4. Richter JE. H pylori: the bug is not all bad. Gut 2001;49:319-20.
5. Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol 2005;36:228-33.
6. Makristathis A, Hirschl AM, Lehours P, Mégraud F. Diagnosis of Helicobacter pylori infection. Helicobacter 2004;9:7-14.
7. Stolte M, Meining A. The updated Sydney system: classification and grading of gastritis as the basis of diagnosis and treatment. Can J Gastroenterol 2001;15:591-8.
8. Manxhuka-Kerliu S, Telaku S, Devolli-Disha E, Ahmetaj H, Sahatciu-Meka V, Kerliu A, Loxha S, Shahini L, Gashi G, Podrimaj A. Helicobacter pylori gastritis updated Sydney classification applied in our material. Prilozi 2009;30:45-60.
9. Lewis SJ, Freedman AR. Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther 1998;12:807-22.
10. Sreeja V, Prajapati JB. Probiotic formulations: application and status as pharmaceuticals-a review. Probiotics Antimicrob Proteins 2013;5:81-91.
11. Cats A, Kuipers EJ, Bosschaert MA, Pot RG, Vandenbroucke-Grauls CM, Kusters JG. Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonizedsubjects. Aliment Pharmacol Ther 2003;17:429-35.
12. Lionetti E, Principi M, Scaccianoce G, Maurogiovanni G, La Rosa M, Ierardi E, et al. Probiotics and Helicobacter pylori. Eur Gastroenterol Hepatol Rev 2011;7:121-8.
13. Lionetti E, Miniello VL, Castellaneta SP, Magistá AM, de Canio A, Maurogiovanni G, et al. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Aliment Pharmacol Ther 2006;24:1461-8.
14. Ruggiero P. Use of probiotics in the fight against Helicobacter pylori. World J Gastrointest Pathophysiol 2014;5:384-91.
15. Emara MH, Mohamed SY, Abdel-Aziz HR. Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: a double-blind placebo-controlled randomized clinical trial. Therap Adv Gastroenterol 2014;7:4-13.
16. Francavilla R, Polimeno L, Demichina A, Maurogiovanni G, Principi B, Scaccianoce G, et al. Lactobacillus reuteristrain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study. J Clin Gastroenterol 2014;48:407-13.
17. Wendakoon CN, Thomson AB, Ozimek L. Lack of therapeutic effect of a specially designed yogurt for the eradication of Helicobacter infection. Digestion 2002;65:16-20.
18. Manfredi M, Bizzarri B, Sacchero RI, Maccari S, Calabrese L, Fabbian F, et al. Helicobacter pylori infection in clinical practice: probiotics anda combination of probiotics + lactoferrin improvecompliance, but not eradication, in sequential therapy. Helicobacter 2012;17:254-63.
19. Francavilla R, Lionetti E, Castellaneta S, Magistà A, Maurogiovanni G, Bucci N, et al. Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter 2008;13:127-34.
20. Felley C, Corthésy-Theulaz I, Rivero J, Sipponen P, Kaufmann M, Bauerfeind P, et al. Favourable effect of an acidified milk (LC-1.) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol 2001;13:25-9.
21. Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008;40:650-8.
22. Walker MM. Is intestinal metaplasia of the stomach reversible? Gut 2003;52:1-4.
23. Toyokawa T, Suwaki K, Miyake Y, Nakatsu M, Ando M. Eradication of Helicobacter pylori infection improved gastric mucosal atrophy and prevented progression of intestinal metaplasia, especially in the elderly population: a long-term prospective cohort study. J Gastroenterol Hepatol 2010;25:544-7.
24. Kuo CH, Wang SS, Lu CY, Hu HM, Kuo FC, Weng BC, et al. Long-term use of probiotic-containing yogurts is a safe way to prevent Helicobacter pylori: based on a mongolian gerbil's model. Biochem Res Int 2013;2013:594561.
25. Pantoflickova D, Corthesy-Theulaz I, Dorta G, Stolte M, Isler P, Rochat F, et al. Favorable effect of long-term intake of fermented milk containing Lactobacillus johnsonii on H. pylori associated gastritis. Aliment Pharmacol Ther 2003;18:805-13.
26. Wang K, Li S, Liu C, Perng D, Su Y, Wu D, et al. Effects of ingesting Lactobacillus and Bifidobacterium-containing yoghurt in subjects with colonized Helicobacter pylori. Am J Clin Nutr 2004;80:737-41.
27. Versalovic J. Helicobacter pylori. Pathology and diagnostic strategies. Am J Clin Pathol 2003;119:403-12.
28. Chauviere G, Coconnier M, Kerneis S, Fourniat J, Servin A. Adhesion of human Lactobacillus acidophilus strain LB to human enterocyte-like Caco-2 cells. J Gen Microbiol 1992;138:1689-96.
29. Conway PL, Kjelleberg S. Protein-mediated adhesion of Lactobacillus fermentum strain 737 to mouse stomach squamous epithelium. J Gen Microbiol 1989;135:1175-86.
30. Mack D, Michail S, Wei S, McDougall L, Hollingsworth M. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999;276:G941-50.
31. Byrd J, Yunker C, Xu Q, Sternberg L, Bresalier R. Inhibition of gastric mucin synthesis by Helicobacter pylori. Gastroenterology 2000;118:1072-9.
32. Hamilton-Miller J. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int J Antimicrob Agents 2003;22:360-6.
33. Spinler J, Taweechotipatr M, Rognerud C, Ou C, Tumwasorn S, Versalovic J. Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe 2008;14:166-71.
34. Thomas C, Hong T, van Pijkeren J, Hemarajata P, Trinh D, Hu W, et al. Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of PKA and ERK signaling. PLoS ONE 2012; 7: e31951.
35. Cunningham-Rundles S, Ahrne S, Bengmark S, Johann-Liang R, Marshall F, Metakis L, et al. Probiotics and immune response. Am J Gastroenterol 2000;95:S22-5.
36. Gill H, Rutherfurd K, Prasad J, Gopal P. Enhancement of natural and acquired immunity by Lactobacillus rhamnosus (HN001), Lactobacillus acidophilus (HN017) and Bifidobacterium lactis (HN019). Br J Nutr 2000;83:167-76.
37. Vitini E, Alvarez S, Medina M, Medici M, de Budeguer M, Perdigon G. Gut mucosal immunostimulation by lactic acid bacteria. Biocell 2000;24:223-32.
38. Bamford KB, Fan X, Crowe SE, Leary JF, Gourley WK, Luthra GK, et al. Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype. Gastroenterology 1998;114:482-92.
39. Marshall B, Armstrong J, Francis G, Nokes N, Wee S. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion 1987;37:16-30.
40. Graham D, Opekun A, Klein P. Clarithromycin for the eradication of Helicobacter pylori. J Clin Gastroenterol 1993;16:292-4.
41. Stolte M, Stadelmann O, Bethke B. Relationships between the degree of Helicobacter pylori colonization and the degree and activity of gastritis, surface epithelial degeneration and mucus secretion. Z Gastroenterol 1995;33:89-93.
42. Zhu R, Chen K, Zheng YY, Zhang HW, Wang JS, Xia YJ, et al. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol 2014;20:18013-21.